[Antibody formation after filtered blood cell replacement in hematologic-oncologic patients].
We studied the value of leucocyte depletion of platelet and erythrocyte transfusion by filter for the prevention of alloimmunization. In 109 patients with hematological diseases we detected HLA- and platelet specific antibodies by using lymphocytotoxic and IgG-EIA-Thrombomatch. In 17 of the 109 evaluable patients (16%) HLA-antibodies developed (9 female and 8 male). 16 of the 17 had only HLA-antibodies and 1 patient a platelet specific alloantibody primary immunisation. 15 of 17 with a high-risk of prior immunization induced by pregnancy or other transfusions had a 'secondary alloimmunization'.
Barz
D
D
Abteilung Transfusionsmedizin, Universität Rostock, Deutschland.
Staack
D
D
Lehmann
R
R
Stange
K
K
Schnurstein
K
K
D000328:Adult; D001788:Blood Grouping and Crossmatching; D004797:Enzyme-Linked Immunosorbent Assay; D017707:Erythrocyte Transfusion; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007518:Isoantibodies / Q000032:analysis*; D007938:Leukemia / Q000097:blood / Q000628:therapy*; D008212:Lymphocyte Depletion; D008223:Lymphoma / Q000097:blood / Q000628:therapy*; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000628:therapy*; D017713:Platelet Transfusion; D011247:Pregnancy; D012307:Risk Factors
D006680:HLA Antigens; D007518:Isoantibodies
Antikörperbildung nach filtriertem Blutzellersatz bei hämatologisch-onkologischen Patienten.